ENDPQ

false2022FY0001593034http://fasb.org/us-gaap/2022#BusinessCombinationAcquisitionRelatedCostshttp://fasb.org/us-gaap/2022#BusinessCombinationAcquisitionRelatedCostshttp://fasb.org/us-gaap/2022#BusinessCombinationAcquisitionRelatedCostshttp://fasb.org/us-gaap/2022#BusinessCombinationAcquisitionRelatedCostshttp://fasb.org/us-gaap/2022#BusinessCombinationAcquisitionRelatedCostshttp://fasb.org/us-gaap/2022#BusinessCombinationAcquisitionRelatedCostshttp://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrenthttp://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrenthttp://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#AssetImpairmentChargeshttp://fasb.org/us-gaap/2022#AssetImpairmentChargesP8DP3Y00015930342022-01-012022-12-3100015930342022-06-30iso4217:USD00015930342023-02-27xbrli:shares0001593034us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-12-310001593034us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-01-012020-12-310001593034us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-12-310001593034us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-01-012021-12-310001593034us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-12-310001593034us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-01-012022-12-310001593034us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-12-310001593034endp:OpioidRelatedCasesMemberendp:AdHocFirstLienGroupMember2022-12-3100015930342022-12-3100015930342021-12-31iso4217:USDxbrli:shares00015930342021-01-012021-12-3100015930342020-01-012020-12-310001593034us-gaap:CommonStockMember2019-12-310001593034endp:EuroDeferredSharesMember2019-12-310001593034us-gaap:AdditionalPaidInCapitalMember2019-12-310001593034us-gaap:RetainedEarningsMember2019-12-310001593034us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-3100015930342019-12-310001593034us-gaap:RetainedEarningsMember2020-01-012020-12-310001593034us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001593034us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001593034us-gaap:CommonStockMember2020-01-012020-12-310001593034endp:EuroDeferredSharesMember2020-01-012020-12-310001593034us-gaap:CommonStockMember2020-12-310001593034endp:EuroDeferredSharesMember2020-12-310001593034us-gaap:AdditionalPaidInCapitalMember2020-12-310001593034us-gaap:RetainedEarningsMember2020-12-310001593034us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100015930342020-12-310001593034us-gaap:RetainedEarningsMember2021-01-012021-12-310001593034us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001593034us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001593034us-gaap:CommonStockMember2021-01-012021-12-310001593034endp:EuroDeferredSharesMember2021-01-012021-12-310001593034us-gaap:CommonStockMember2021-12-310001593034endp:EuroDeferredSharesMember2021-12-310001593034us-gaap:AdditionalPaidInCapitalMember2021-12-310001593034us-gaap:RetainedEarningsMember2021-12-310001593034us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001593034us-gaap:RetainedEarningsMember2022-01-012022-12-310001593034us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001593034us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001593034us-gaap:CommonStockMember2022-01-012022-12-310001593034endp:EuroDeferredSharesMember2022-01-012022-12-310001593034us-gaap:CommonStockMember2022-12-310001593034endp:EuroDeferredSharesMember2022-12-310001593034us-gaap:AdditionalPaidInCapitalMember2022-12-310001593034us-gaap:RetainedEarningsMember2022-12-310001593034us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001593034endp:RestructuringSupportAgreementMember2022-08-16xbrli:pure0001593034endp:StalingHorseBidMember2022-08-160001593034endp:StalingHorseBidMember2022-08-162022-08-160001593034endp:StalingHorseBidMember2022-08-172022-08-1700015930342022-10-3100015930342022-08-172022-12-310001593034us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberendp:AmerisourceBergenCorporationMember2022-01-012022-12-310001593034us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberendp:AmerisourceBergenCorporationMember2021-01-012021-12-310001593034us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberendp:AmerisourceBergenCorporationMember2020-01-012020-12-310001593034us-gaap:CustomerConcentrationRiskMemberendp:MckessonCorporationMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310001593034us-gaap:CustomerConcentrationRiskMemberendp:MckessonCorporationMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-12-310001593034us-gaap:CustomerConcentrationRiskMemberendp:MckessonCorporationMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-12-310001593034us-gaap:CustomerConcentrationRiskMemberendp:CardinalHealthIncMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310001593034us-gaap:CustomerConcentrationRiskMemberendp:CardinalHealthIncMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-12-310001593034us-gaap:CustomerConcentrationRiskMemberendp:CardinalHealthIncMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-12-310001593034endp:XiaflexMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310001593034endp:XiaflexMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-12-310001593034endp:XiaflexMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-12-310001593034us-gaap:ProductConcentrationRiskMemberendp:VareniclineTabletsMemberus-gaap:RevenueFromContractWithCustomerMembersrt:MaximumMember2022-01-012022-12-310001593034us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberendp:VasostrictMember2022-01-012022-12-310001593034us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberendp:VasostrictMember2021-01-012021-12-310001593034us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberendp:VasostrictMember2020-01-012020-12-310001593034srt:MinimumMember2022-01-012022-12-310001593034us-gaap:TradeAccountsReceivableMemberendp:AmerisourceBergenCorporationMemberus-gaap:CreditConcentrationRiskMember2022-01-012022-12-310001593034endp:CardinalHealthIncMemberus-gaap:TradeAccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2022-01-012022-12-310001593034endp:MckessonCorporationMemberus-gaap:TradeAccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2022-01-012022-12-310001593034endp:CardinalHealthIncMemberus-gaap:TradeAccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-12-310001593034endp:MckessonCorporationMemberus-gaap:TradeAccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-12-310001593034us-gaap:TradeAccountsReceivableMemberendp:AmerisourceBergenCorporationMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-12-310001593034srt:MinimumMemberus-gaap:BuildingMember2022-01-012022-12-310001593034us-gaap:BuildingMembersrt:MaximumMember2022-01-012022-12-310001593034us-gaap:MachineryAndEquipmentMember2022-01-012022-12-310001593034endp:ComputerEquipmentAndSoftwareMember2022-01-012022-12-310001593034us-gaap:FurnitureAndFixturesMember2022-01-012022-12-310001593034srt:MinimumMemberus-gaap:DevelopedTechnologyRightsMember2022-01-012022-12-310001593034us-gaap:DevelopedTechnologyRightsMembersrt:MaximumMember2022-01-012022-12-310001593034srt:WeightedAverageMemberus-gaap:DevelopedTechnologyRightsMember2022-01-012022-12-310001593034srt:MinimumMemberus-gaap:LicensingAgreementsMember2022-01-012022-12-310001593034us-gaap:LicensingAgreementsMembersrt:MaximumMember2022-01-012022-12-310001593034srt:WeightedAverageMemberus-gaap:LicensingAgreementsMember2022-01-012022-12-310001593034endp:AstoraMemberus-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember2022-01-012022-12-310001593034endp:AstoraMemberus-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember2021-01-012021-12-310001593034endp:AstoraMemberus-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember2020-01-012020-12-310001593034endp:ManufacturingFacilitiesInChestnutRidgeNYAndIrvineCAAndUSProductRegulatoryApprovalsAndCertainRelatedProductInventoryMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2021-01-012021-12-310001593034us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberendp:EndoInternationalPLCMember2021-01-012021-12-310001593034endp:ManufacturingFacilitiesInChestnutRidgeNYAndIrvineCAAndUSProductRegulatoryApprovalsAndCertainRelatedProductInventoryMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-10-012022-12-310001593034endp:ManufacturingFacilitiesInChestnutRidgeNYAndIrvineCAAndUSProductRegulatoryApprovalsAndCertainRelatedProductInventoryMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberendp:RestructuringInitiative2020Member2022-10-012022-12-310001593034endp:RestructuringInitiative2020Member2020-11-012020-11-30endp:position0001593034srt:MinimumMemberendp:RestructuringInitiative2020Member2020-11-300001593034endp:RestructuringInitiative2020Membersrt:MaximumMember2020-11-300001593034us-gaap:CostOfSalesMembersrt:MinimumMemberendp:RestructuringInitiative2020Member2020-11-300001593034us-gaap:CostOfSalesMemberendp:RestructuringInitiative2020Membersrt:MaximumMember2020-11-300001593034srt:MinimumMemberendp:OtherExpensesMemberendp:RestructuringInitiative2020Member2020-11-300001593034endp:OtherExpensesMemberendp:RestructuringInitiative2020Membersrt:MaximumMember2020-11-300001593034endp:RestructuringInitiative2020Member2022-01-012022-12-310001593034endp:RestructuringInitiative2020Member2021-01-012021-12-310001593034endp:RestructuringInitiative2020Member2020-01-012020-12-310001593034endp:RestructuringInitiative2020Memberus-gaap:OperatingSegmentsMemberendp:GenericPharmaceuticalsSegmentMember2022-01-012022-12-310001593034endp:RestructuringInitiative2020Memberus-gaap:OperatingSegmentsMemberendp:GenericPharmaceuticalsSegmentMember2021-01-012021-12-310001593034endp:RestructuringInitiative2020Memberus-gaap:OperatingSegmentsMemberendp:GenericPharmaceuticalsSegmentMember2020-01-012020-12-310001593034endp:RestructuringInitiative2020Memberendp:AcceleratedDepreciationChargesMember2022-12-310001593034endp:RestructuringInitiative2020Memberendp:AssetImpairmentChargesMember2022-12-310001593034endp:RestructuringInitiative2020Memberendp:InventoryAdjustmentsMember2022-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsMember2022-12-310001593034us-gaap:OtherRestructuringMemberendp:RestructuringInitiative2020Member2022-12-310001593034endp:RestructuringInitiative2020Memberus-gaap:OperatingSegmentsMemberendp:GenericPharmaceuticalsSegmentMember2022-12-310001593034us-gaap:CostOfSalesMemberendp:RestructuringInitiative2020Member2022-01-012022-12-310001593034us-gaap:CostOfSalesMemberendp:RestructuringInitiative2020Member2021-01-012021-12-310001593034us-gaap:CostOfSalesMemberendp:RestructuringInitiative2020Member2020-01-012020-12-310001593034endp:RestructuringInitiative2020Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310001593034endp:RestructuringInitiative2020Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310001593034endp:RestructuringInitiative2020Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310001593034endp:RestructuringInitiative2020Memberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001593034endp:RestructuringInitiative2020Memberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001593034endp:RestructuringInitiative2020Memberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001593034endp:AssetImpairmentChargesMemberendp:RestructuringInitiative2020Member2022-01-012022-12-310001593034endp:AssetImpairmentChargesMemberendp:RestructuringInitiative2020Member2021-01-012021-12-310001593034endp:AssetImpairmentChargesMemberendp:RestructuringInitiative2020Member2020-01-012020-12-310001593034endp:RestructuringInitiative2020Memberus-gaap:OtherOperatingIncomeExpenseMember2022-01-012022-12-310001593034endp:RestructuringInitiative2020Memberus-gaap:OtherOperatingIncomeExpenseMember2021-01-012021-12-310001593034endp:RestructuringInitiative2020Memberus-gaap:OtherOperatingIncomeExpenseMember2020-01-012020-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsMember2019-12-310001593034us-gaap:OtherRestructuringMemberendp:RestructuringInitiative2020Member2019-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsAndOtherRestructuringCostsMember2019-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsMember2020-01-012020-12-310001593034us-gaap:OtherRestructuringMemberendp:RestructuringInitiative2020Member2020-01-012020-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsAndOtherRestructuringCostsMember2020-01-012020-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsMember2020-12-310001593034us-gaap:OtherRestructuringMemberendp:RestructuringInitiative2020Member2020-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsAndOtherRestructuringCostsMember2020-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsMember2021-01-012021-12-310001593034us-gaap:OtherRestructuringMemberendp:RestructuringInitiative2020Member2021-01-012021-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsAndOtherRestructuringCostsMember2021-01-012021-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsMember2021-12-310001593034us-gaap:OtherRestructuringMemberendp:RestructuringInitiative2020Member2021-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsAndOtherRestructuringCostsMember2021-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsMember2022-01-012022-12-310001593034us-gaap:OtherRestructuringMemberendp:RestructuringInitiative2020Member2022-01-012022-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsAndOtherRestructuringCostsMember2022-01-012022-12-310001593034endp:RestructuringInitiative2020Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsAndOtherRestructuringCostsMember2022-12-310001593034endp:RestructuringInitiativeApril2022Member2022-04-012022-04-300001593034srt:MinimumMemberendp:RestructuringInitiativeApril2022Member2022-04-300001593034endp:RestructuringInitiativeApril2022Membersrt:MaximumMember2022-04-300001593034endp:RestructuringInitiativeApril2022Member2022-01-012022-12-310001593034endp:RestructuringInitiativeApril2022Memberus-gaap:OperatingSegmentsMemberendp:GenericPharmaceuticalsSegmentMember2022-01-012022-12-310001593034us-gaap:CostOfSalesMemberendp:RestructuringInitiativeApril2022Member2022-01-012022-12-310001593034endp:RestructuringInitiativeApril2022Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310001593034endp:RestructuringInitiativeApril2022Memberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001593034endp:AssetImpairmentChargesMemberendp:RestructuringInitiativeApril2022Member2022-01-012022-12-310001593034endp:RestructuringInitiativeApril2022Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsMember2021-12-310001593034us-gaap:OtherRestructuringMemberendp:RestructuringInitiativeApril2022Member2021-12-310001593034endp:RestructuringInitiativeApril2022Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsAndOtherRestructuringCostsMember2021-12-310001593034endp:RestructuringInitiativeApril2022Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsMember2022-01-012022-12-310001593034us-gaap:OtherRestructuringMemberendp:RestructuringInitiativeApril2022Member2022-01-012022-12-310001593034endp:RestructuringInitiativeApril2022Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsAndOtherRestructuringCostsMember2022-01-012022-12-310001593034endp:RestructuringInitiativeApril2022Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsMember2022-12-310001593034us-gaap:OtherRestructuringMemberendp:RestructuringInitiativeApril2022Member2022-12-310001593034endp:RestructuringInitiativeApril2022Memberendp:EmployeeSeparationContinuityAndOtherBenefitRelatedCostsAndOtherRestructuringCostsMember2022-12-31endp:segment0001593034endp:BrandedPharmaceuticalsSegmentMember2022-01-012022-12-310001593034endp:BrandedPharmaceuticalsSegmentMember2021-01-012021-12-310001593034endp:BrandedPharmaceuticalsSegmentMember2020-01-012020-12-310001593034endp:SterileInjectablesSegmentMember2022-01-012022-12-310001593034endp:SterileInjectablesSegmentMember2021-01-012021-12-310001593034endp:SterileInjectablesSegmentMember2020-01-012020-12-310001593034endp:GenericPharmaceuticalsSegmentMember2022-01-012022-12-310001593034endp:GenericPharmaceuticalsSegmentMember2021-01-012021-12-310001593034endp:GenericPharmaceuticalsSegmentMember2020-01-012020-12-310001593034endp:InternationalPharmaceuticalsSegmentMember2022-01-012022-12-310001593034endp:InternationalPharmaceuticalsSegmentMember2021-01-012021-12-310001593034endp:InternationalPharmaceuticalsSegmentMember2020-01-012020-12-310001593034us-gaap:MaterialReconcilingItemsMember2022-01-012022-12-310001593034us-gaap:MaterialReconcilingItemsMember2021-01-012021-12-310001593034us-gaap:MaterialReconcilingItemsMember2020-01-012020-12-310001593034us-gaap:OperatingSegmentsMember2022-01-012022-12-310001593034us-gaap:OperatingSegmentsMember2021-01-012021-12-310001593034us-gaap:OperatingSegmentsMember2020-01-012020-12-310001593034endp:CostReductionMemberus-gaap:EmployeeSeveranceMember2022-01-012022-12-310001593034endp:CostReductionMember2022-01-012022-12-310001593034endp:CostReductionMemberendp:InventoryAdjustmentsMember2022-01-012022-12-310001593034us-gaap:OtherRestructuringMemberendp:CostReductionMember2022-01-012022-12-310001593034endp:CostReductionMemberus-gaap:EmployeeSeveranceMember2021-01-012021-12-310001593034endp:CostReductionMember2021-01-012021-12-310001593034us-gaap:OtherRestructuringMemberendp:CostReductionMember2021-01-012021-12-310001593034endp:CostReductionMemberus-gaap:EmployeeSeveranceMember2020-01-012020-12-310001593034endp:CostReductionMember2020-01-012020-12-310001593034us-gaap:OtherRestructuringMemberendp:CostReductionMember2020-01-012020-12-310001593034us-gaap:SellingGeneralAndAdministrativeExpensesMemberendp:SixPointOneTwoFivePercentSeniorNotesDueTwoThousandTwentyNineMember2021-01-012021-12-310001593034us-gaap:SellingGeneralAndAdministrativeExpensesMemberendp:SixPointOneTwoFivePercentSeniorNotesDueTwoThousandTwentyNineMember2020-01-012020-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:XiaflexMember2022-01-012022-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:XiaflexMember2021-01-012021-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:XiaflexMember2020-01-012020-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:SUPPRELINLAMember2022-01-012022-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:SUPPRELINLAMember2021-01-012021-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:SUPPRELINLAMember2020-01-012020-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:OtherSpecialtyProductsMember2022-01-012022-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:OtherSpecialtyProductsMember2021-01-012021-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:OtherSpecialtyProductsMember2020-01-012020-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:SpecialtyProductsMember2022-01-012022-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:SpecialtyProductsMember2021-01-012021-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:SpecialtyProductsMember2020-01-012020-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:PERCOCETMember2022-01-012022-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:PERCOCETMember2021-01-012021-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:PERCOCETMember2020-01-012020-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:LidodermMember2022-01-012022-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:LidodermMember2021-01-012021-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:LidodermMember2020-01-012020-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:OtherEstablishedProductsMember2022-01-012022-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:OtherEstablishedProductsMember2021-01-012021-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:OtherEstablishedProductsMember2020-01-012020-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:EstablishedProductsMember2022-01-012022-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:EstablishedProductsMember2021-01-012021-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberendp:EstablishedProductsMember2020-01-012020-12-310001593034endp:SterileInjectablesSegmentMemberendp:VasostrictMember2022-01-012022-12-310001593034endp:SterileInjectablesSegmentMemberendp:VasostrictMember2021-01-012021-12-310001593034endp:SterileInjectablesSegmentMemberendp:VasostrictMember2020-01-012020-12-310001593034endp:AdrenalinMemberendp:SterileInjectablesSegmentMember2022-01-012022-12-310001593034endp:AdrenalinMemberendp:SterileInjectablesSegmentMember2021-01-012021-12-310001593034endp:AdrenalinMemberendp:SterileInjectablesSegmentMember2020-01-012020-12-310001593034endp:OtherSterileInjectablesMemberendp:SterileInjectablesSegmentMember2022-01-012022-12-310001593034endp:OtherSterileInjectablesMemberendp:SterileInjectablesSegmentMember2021-01-012021-12-310001593034endp:OtherSterileInjectablesMemberendp:SterileInjectablesSegmentMember2020-01-012020-12-310001593034us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberendp:InternationalPharmaceuticalsSegmentMembersrt:MaximumMember2022-01-012022-12-310001593034us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberendp:InternationalPharmaceuticalsSegmentMembersrt:MaximumMember2021-01-012021-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001593034us-gaap:OperatingSegmentsMemberendp:SterileInjectablesSegmentMember2022-01-012022-12-310001593034us-gaap:OperatingSegmentsMemberendp:SterileInjectablesSegmentMember2021-01-012021-12-310001593034us-gaap:OperatingSegmentsMemberendp:SterileInjectablesSegmentMember2020-01-012020-12-310001593034us-gaap:OperatingSegmentsMemberendp:GenericPharmaceuticalsSegmentMember2022-01-012022-12-310001593034us-gaap:OperatingSegmentsMemberendp:GenericPharmaceuticalsSegmentMember2021-01-012021-12-310001593034us-gaap:OperatingSegmentsMemberendp:GenericPharmaceuticalsSegmentMember2020-01-012020-12-310001593034us-gaap:OperatingSegmentsMemberendp:InternationalPharmaceuticalsSegmentMember2022-01-012022-12-310001593034us-gaap:OperatingSegmentsMemberendp:InternationalPharmaceuticalsSegmentMember2021-01-012021-12-310001593034us-gaap:OperatingSegmentsMemberendp:InternationalPharmaceuticalsSegmentMember2020-01-012020-12-310001593034us-gaap:CorporateNonSegmentMember2022-01-012022-12-310001593034us-gaap:CorporateNonSegmentMember2021-01-012021-12-310001593034us-gaap:CorporateNonSegmentMember2020-01-012020-12-310001593034endp:OpioidRelatedCasesAndMeshRelatedCasesMember2022-12-310001593034endp:OpioidRelatedCasesAndMeshRelatedCasesMember2021-12-310001593034endp:RestrictedCashAndCashEquivalentsInsuranceCoverageMember2022-12-310001593034endp:RestrictedCashAndCashEquivalentsInsuranceCoverageMember2021-12-310001593034us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310001593034us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2022-12-310001593034us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2022-12-310001593034us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001593034us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-12-310001593034us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2021-12-310001593034us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-12-310001593034us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001593034us-gaap:MoneyMarketFundsMemberendp:RestrictedCashAndCashEquivalentsMember2022-12-310001593034us-gaap:MoneyMarketFundsMemberendp:RestrictedCashAndCashEquivalentsMember2021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberus-gaap:OtherLiabilitiesMember2021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMember2021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMember2020-12-310001593034endp:AcquisitionRelatedContingentConsiderationMember2022-01-012022-12-310001593034endp:AcquisitionRelatedContingentConsiderationMember2021-01-012021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMember2022-12-310001593034srt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2022-12-310001593034srt:MaximumMemberus-gaap:MeasurementInputDiscountRateMember2022-12-310001593034srt:WeightedAverageMemberus-gaap:MeasurementInputDiscountRateMember2022-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:AuxiliumPharmaceuticalsInc.Member2021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:AuxiliumPharmaceuticalsInc.Member2022-01-012022-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:AuxiliumPharmaceuticalsInc.Member2022-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:LehighValleyTechnologiesInc.Member2021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:LehighValleyTechnologiesInc.Member2022-01-012022-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:LehighValleyTechnologiesInc.Member2022-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:OtherAcquisitionsExcludingVoltarenMember2021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:OtherAcquisitionsExcludingVoltarenMember2022-01-012022-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:OtherAcquisitionsExcludingVoltarenMember2022-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:AuxiliumPharmaceuticalsInc.Member2020-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:AuxiliumPharmaceuticalsInc.Member2021-01-012021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:LehighValleyTechnologiesInc.Member2020-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:LehighValleyTechnologiesInc.Member2021-01-012021-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:OtherAcquisitionsExcludingVoltarenMember2020-12-310001593034endp:AcquisitionRelatedContingentConsiderationMemberendp:OtherAcquisitionsExcludingVoltarenMember2021-01-012021-12-310001593034us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001593034us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001593034us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001593034us-gaap:FairValueMeasurementsNonrecurringMember2022-01-012022-12-310001593034us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001593034us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001593034us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001593034us-gaap:FairValueMeasurementsNonrecurringMember2021-01-012021-12-310001593034us-gaap:FairValueMeasurementsNonrecurringMembersrt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2022-12-310001593034us-gaap:FairValueMeasurementsNonrecurringMembersrt:MaximumMemberus-gaap:MeasurementInputDiscountRateMember2022-12-310001593034srt:WeightedAverageMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:MeasurementInputDiscountRateMember2022-12-310001593034us-gaap:FairValueMeasurementsNonrecurringMembersrt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2021-12-310001593034us-gaap:FairValueMeasurementsNonrecurringMembersrt:MaximumMemberus-gaap:MeasurementInputDiscountRateMember2021-12-310001593034srt:WeightedAverageMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:MeasurementInputDiscountRateMember2021-12-31endp:renewal_options0001593034us-gaap:CostOfSalesMember2022-01-012022-12-310001593034us-gaap:CostOfSalesMember2021-01-012021-12-310001593034us-gaap:CostOfSalesMember2020-01-012020-12-310001593034us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310001593034us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310001593034us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310001593034us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001593034us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001593034us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001593034us-gaap:LandAndBuildingMember2022-12-310001593034us-gaap:LandAndBuildingMember2021-12-310001593034us-gaap:MachineryAndEquipmentMember2022-12-310001593034us-gaap:MachineryAndEquipmentMember2021-12-310001593034us-gaap:LeaseholdImprovementsMember2022-12-310001593034us-gaap:LeaseholdImprovementsMember2021-12-310001593034endp:ComputerEquipmentAndSoftwareMember2022-12-310001593034endp:ComputerEquipmentAndSoftwareMember2021-12-310001593034us-gaap:FurnitureAndFixturesMember2022-12-310001593034us-gaap:FurnitureAndFixturesMember2021-12-310001593034us-gaap:AssetUnderConstructionMember2022-12-310001593034us-gaap:AssetUnderConstructionMember2021-12-310001593034country:IN2022-12-310001593034country:IN2021-12-310001593034endp:BrandedPharmaceuticalsSegmentMember2020-12-310001593034endp:SterileInjectablesSegmentMember2020-12-310001593034endp:GenericPharmaceuticalsSegmentMember2020-12-310001593034endp:InternationalPharmaceuticalsSegmentMember2020-12-310001593034endp:BrandedPharmaceuticalsSegmentMember2021-12-310001593034endp:SterileInjectablesSegmentMember2021-12-310001593034endp:GenericPharmaceuticalsSegmentMember2021-12-310001593034endp:InternationalPharmaceuticalsSegmentMember2021-12-310001593034endp:BrandedPharmaceuticalsSegmentMember2022-12-310001593034endp:SterileInjectablesSegmentMember2022-12-310001593034endp:GenericPharmaceuticalsSegmentMember2022-12-310001593034endp:InternationalPharmaceuticalsSegmentMember2022-12-310001593034us-gaap:DevelopedTechnologyRightsMember2022-01-012022-12-310001593034us-gaap:LicensingAgreementsMember2021-12-310001593034us-gaap:LicensingAgreementsMember2022-01-012022-12-310001593034us-gaap:LicensingAgreementsMember2022-12-310001593034us-gaap:TradeNamesMember2021-12-310001593034us-gaap:TradeNamesMember2022-01-012022-12-310001593034us-gaap:TradeNamesMember2022-12-310001593034us-gaap:DevelopedTechnologyRightsMember2021-12-310001593034us-gaap:DevelopedTechnologyRightsMember2022-12-310001593034srt:WeightedAverageMember2022-01-012022-12-310001593034endp:BrandedPharmaceuticalsSegmentMemberus-gaap:MeasurementInputDiscountRateMember2022-10-010001593034endp:BrandedPharmaceuticalsSegmentMemberus-gaap:MeasurementInputDiscountRateMember2021-10-010001593034endp:BrandedPharmaceuticalsSegmentMemberus-gaap:MeasurementInputDiscountRateMember2020-10-010001593034endp:SterileInjectablesSegmentMemberus-gaap:MeasurementInputDiscountRateMember2022-10-010001593034endp:SterileInjectablesSegmentMemberus-gaap:MeasurementInputDiscountRateMember2021-10-010001593034endp:SterileInjectablesSegmentMemberus-gaap:MeasurementInputDiscountRateMember2020-10-010001593034endp:SterileInjectablesSegmentMember2021-10-012021-12-310001593034endp:PaladinLabsInc.Memberus-gaap:MeasurementInputDiscountRateMember2020-03-310001593034endp:PaladinLabsInc.Member2020-01-012020-03-310001593034endp:SterileInjectablesMember2022-04-012022-06-300001593034endp:BrandedPharmaceuticalsSegmentMemberus-gaap:MeasurementInputDiscountRateMember2022-07-012022-09-300001593034endp:BrandedPharmaceuticalsSegmentMemberus-gaap:MeasurementInputDiscountRateMember2022-06-300001593034endp:SterileInjectablesSegmentMemberus-gaap:MeasurementInputDiscountRateMember2022-06-300001593034endp:SterileInjectablesMember2022-07-012022-09-300001593034endp:BrandedPharmaceuticalsSegmentMemberus-gaap:MeasurementInputDiscountRateMember2022-09-300001593034endp:SterileInjectablesSegmentMemberus-gaap:MeasurementInputDiscountRateMember2022-09-300001593034endp:BioSpecificsMember2020-10-190001593034endp:BioSpecificsMember2020-12-012020-12-010001593034srt:MinimumMember2020-12-012020-12-010001593034srt:MaximumMember2020-12-012020-12-010001593034endp:BioSpecificsMember2020-12-022020-12-020001593034endp:BioSpecificsMember2020-12-010001593034endp:BioSpecificsMember2020-12-020001593034endp:BioSpecificsMember2020-12-030001593034endp:XIAFLEXAndQWOMemberendp:BioSpecificsMember2022-01-012022-12-310001593034endp:NevakarInjectablesIncMember2022-05-012022-05-31endp:project0001593034endp:TLCAgreementMember2022-04-012022-06-300001593034endp:TLCAgreementMember2022-12-310001593034endp:SevenPointTwoFivePercentSeniorNotesDueTwoThousandTwentyTwoMember2022-12-310001593034endp:SevenPointTwoFivePercentSeniorNotesDueTwoThousandTwentyTwoMember2021-12-310001593034endp:FivePointSevenFiveSeniorNotesDueOnTwoThousandTwentyTwoMember2022-12-310001593034endp:FivePointSevenFiveSeniorNotesDueOnTwoThousandTwentyTwoMember2021-12-310001593034endp:FivePointThreeSevenFiveSeniorNotesDueOnTwoThousandTwentyThreeMember2022-06-300001593034endp:FivePointThreeSevenFiveSeniorNotesDueOnTwoThousandTwentyThreeMember2022-12-310001593034endp:FivePointThreeSevenFiveSeniorNotesDueOnTwoThousandTwentyThreeMember2021-12-310001593034endp:SixPointZeroPercentSeniorNotesDueTwoThousandTwentyThreeMember2022-06-300001593034endp:SixPointZeroPercentSeniorNotesDueTwoThousandTwentyThreeMember2022-12-310001593034endp:SixPointZeroPercentSeniorNotesDueTwoThousandTwentyThreeMember2021-12-310001593034endp:FivePointEightSevenFivePercentSeniorSecuredNotesDueTwentyTwentyFourMember2022-12-310001593034endp:FivePointEightSevenFivePercentSeniorSecuredNotesDueTwentyTwentyFourMember2021-12-310001593034endp:SixPercentSeniorNotesDueTwoThousandTwentyFiveMember2022-06-300001593034endp:SixPercentSeniorNotesDueTwoThousandTwentyFiveMember2022-12-310001593034endp:SixPercentSeniorNotesDueTwoThousandTwentyFiveMember2021-12-310001593034endp:SevenPointFivePercentSeniorSecuredNotesDueTwentyTwentySevenMember2022-12-310001593034endp:SevenPointFivePercentSeniorSecuredNotesDueTwentyTwentySevenMember2021-12-310001593034endp:NinePointFivePercentSeniorNotesDueTwoThousandTwentySevenMember2022-06-300001593034endp:NinePointFivePercentSeniorNotesDueTwoThousandTwentySevenMember2022-12-310001593034endp:NinePointFivePercentSeniorNotesDueTwoThousandTwentySevenMember2021-12-310001593034endp:SixPercentSeniorNotesDueTwoThousandTwentyEightMember2022-06-300001593034endp:SixPercentSeniorNotesDueTwoThousandTwentyEightMember2022-12-310001593034endp:SixPercentSeniorNotesDueTwoThousandTwentyEightMember2021-12-310001593034endp:SixPointOneTwoFivePercentSeniorNotesDueTwoThousandTwentyNineMember2022-12-310001593034endp:SixPointOneTwoFivePercentSeniorNotesDueTwoThousandTwentyNineMember2021-12-310001593034endp:TermLoanFacilityMember2022-12-310001593034endp:TermLoanFacilityMember2021-12-310001593034us-gaap:RevolvingCreditFacilityMember2022-12-310001593034us-gaap:RevolvingCreditFacilityMember2021-12-3100015930342022-07-012022-09-300001593034us-gaap:RevolvingCreditFacilityMemberendp:A2017CreditAgreementMember2022-12-310001593034endp:A2017CreditAgreementMemberus-gaap:SecuredDebtMember2022-12-310001593034endp:TermLoanFacilityMember2022-12-310001593034us-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2022-01-012022-12-310001593034us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2022-01-012022-12-310001593034us-gaap:BaseRateMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2022-01-012022-12-310001593034us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2022-01-012022-12-310001593034us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:SecuredDebtMember2022-01-012022-12-310001593034us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:SecuredDebtMember2022-12-310001593034us-gaap:BaseRateMemberus-gaap:SecuredDebtMember2022-01-012022-12-310001593034us-gaap:BaseRateMemberus-gaap:SecuredDebtMember2022-12-3100015930342022-04-012022-06-3000015930342022-10-012022-12-310001593034us-gaap:SeniorNotesMember2022-12-310001593034us-gaap:RevolvingCreditFacilityMember2022-01-012022-12-310001593034endp:TermLoanFacilityMember2022-01-012022-12-310001593034us-gaap:SeniorNotesMember2022-01-012022-12-3100015930342020-06-012020-06-3000015930342020-04-012020-06-300001593034endp:FivePointSevenFiveSeniorNotesDueOnTwoThousandTwentyTwoMember2020-08-310001593034endp:TermLoanFacilityMember2021-02-280001593034endp:TermLoanFacilityMember2021-03-012021-03-310001593034endp:SixPointOneTwoFivePercentSeniorNotesDueTwoThousandTwentyNineMember2021-03-310001593034us-gaap:RevolvingCreditFacilityMember2021-03-310001593034endp:TermLoanFacilityMember2021-01-012021-03-310001593034endp:SixPointOneTwoFivePercentSeniorNotesDueTwoThousandTwentyNineMember2021-01-012021-03-310001593034us-gaap:SellingGeneralAndAdministrativeExpensesMemberendp:SixPointOneTwoFivePercentSeniorNotesDueTwoThousandTwentyNineMember2021-01-012021-03-310001593034us-gaap:RevolvingCreditFacilityMember2021-01-012021-03-310001593034us-gaap:RevolvingCreditFacilityMember2021-10-012021-10-310001593034endp:SevenPointTwoFivePercentSeniorNotesDueTwoThousandTwentyTwoMember2021-10-310001593034endp:FivePointSevenFiveSeniorNotesDueOnTwoThousandTwentyTwoMember2021-10-310001593034us-gaap:SeniorNotesMember2021-10-012021-10-310001593034endp:PropertyPlantAndEquipmentsMember2022-01-012022-12-310001593034us-gaap:OtherLiabilitiesMember2022-01-012022-12-310001593034endp:SellingGeneralAndAdministrativeExpensesAndCostOfRevenuesMember2022-01-012022-12-310001593034endp:MeshRelatedCasesMemberendp:AmericanMedicalSystemsMember2022-01-012022-12-31endp:case0001593034endp:MeshRelatedCasesMember2021-12-310001593034endp:MeshRelatedCasesMemberendp:ProductLiabilityMember2021-12-310001593034endp:MeshRelatedCasesMember2022-01-012022-12-310001593034endp:MeshRelatedCasesMemberendp:ProductLiabilityMember2022-01-012022-12-310001593034endp:MeshRelatedCasesMember2022-12-310001593034endp:MeshRelatedCasesMemberendp:ProductLiabilityMember2022-12-310001593034endp:OpioidRelatedCasesMemberus-gaap:SubsequentEventMember2023-02-270001593034endp:OpioidRelatedCasesMember2022-01-012022-12-31endp:lawsuit0001593034endp:OpioidRelatedCasesMember2019-09-012019-09-300001593034endp:VASOSTRICTandorADRENALINMemberendp:OpioidRelatedCasesMember2019-09-012019-09-300001593034endp:OpioidRelatedCasesMember2020-01-012020-01-310001593034endp:OpioidRelatedCasesMember2021-08-012021-08-31endp:countyendp:municipality0001593034endp:OpioidRelatedCasesMemberstpr:NY2021-09-012021-09-300001593034endp:OpioidRelatedCasesMember2021-09-012021-09-300001593034endp:OpioidRelatedCasesMemberendp:EndoInternationalPLCMember2021-10-012021-10-310001593034endp:OpioidRelatedCasesMemberstpr:TX2021-12-012021-12-310001593034endp:OpioidRelatedCasesMemberendp:EndoInternationalPLCMember2021-12-012021-12-310001593034endp:OpioidRelatedCasesMemberendp:EndoInternationalPLCMember2022-01-012022-01-310001593034endp:OpioidRelatedCasesMemberendp:EndoInternationalPLCMember2022-02-012022-02-280001593034endp:OpioidRelatedCasesMemberendp:EndoInternationalPLCMember2022-03-012022-03-310001593034endp:OpioidRelatedCasesMemberendp:EndoInternationalPLCMember2022-06-012022-06-300001593034endp:OpioidRelatedCasesMemberendp:EndoInternationalPLCMember2022-07-012022-07-310001593034endp:OpioidRelatedCasesMemberendp:SanFranciscoMember2022-07-012022-07-310001593034endp:OpioidRelatedCasesMemberendp:AdHocFirstLienGroupMember2022-08-160001593034endp:OpioidRelatedCasesMemberendp:AdHocFirstLienGroupMember2022-08-162022-08-160001593034endp:OpioidRelatedCasesMemberendp:AdHocFirstLienGroupMember2022-07-012022-09-300001593034endp:OpioidRelatedCasesMemberendp:AdHocFirstLienGroupMember2022-09-300001593034endp:OpioidRelatedCasesMemberendp:AdHocFirstLienGroupMemberus-gaap:SubsequentEventMember2023-03-030001593034endp:OpioidRelatedCasesMemberendp:AdHocFirstLienGroupMember2022-10-012022-12-310001593034endp:DistrictCourtForTheEasternDistrictOfPennsylvaniaMember2016-03-310001593034endp:VASOSTRICTRelatedMattersMemberendp:ParPharmaceuticalIncMember2022-03-012022-03-31endp:shareholder0001593034endp:A2015ShareBuybackProgramMember2022-12-310001593034endp:A2015ShareBuybackProgramMember2022-01-012022-12-310001593034endp:PlansOtherThan2015PlanMember2022-12-310001593034endp:TwoThousandFifteenStockIncentivePlanMember2022-12-310001593034us-gaap:EmployeeStockOptionMembersrt:MinimumMember2022-01-012022-12-310001593034us-gaap:EmployeeStockOptionMembersrt:MaximumMember2022-01-012022-12-310001593034us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001593034srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001593034us-gaap:PerformanceSharesMember2022-01-012022-12-310001593034us-gaap:PerformanceSharesMembersrt:MinimumMember2022-01-012022-12-310001593034us-gaap:PerformanceSharesMembersrt:MaximumMember2022-01-012022-12-310001593034endp:RestrictedStockUnitsAndPerformanceStockUnitsMember2019-12-310001593034endp:RestrictedStockUnitsAndPerformanceStockUnitsMember2020-01-012020-12-310001593034endp:RestrictedStockUnitsAndPerformanceStockUnitsMember2020-12-310001593034endp:RestrictedStockUnitsAndPerformanceStockUnitsMember2021-01-012021-12-310001593034endp:RestrictedStockUnitsAndPerformanceStockUnitsMember2021-12-310001593034endp:RestrictedStockUnitsAndPerformanceStockUnitsMember2022-01-012022-12-310001593034endp:RestrictedStockUnitsAndPerformanceStockUnitsMember2022-12-310001593034us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001593034us-gaap:RestrictedStockUnitsRSUMember2022-12-310001593034us-gaap:PerformanceSharesMember2022-12-310001593034us-gaap:RestrictedStockUnitsRSUMember2021-12-310001593034us-gaap:RestrictedStockUnitsRSUMember2020-12-310001593034us-gaap:ForeignCountryMemberus-gaap:RevenueCommissionersIrelandMember2022-12-310001593034us-gaap:ForeignCountryMemberus-gaap:LuxembourgInlandRevenueMember2022-12-310001593034country:US2022-12-310001593034us-gaap:CapitalLossCarryforwardMembercountry:US2022-12-310001593034us-gaap:GeneralBusinessMembercountry:US2022-12-310001593034us-gaap:StateAndLocalJurisdictionMember2022-12-310001593034us-gaap:CapitalLossCarryforwardMemberus-gaap:StateAndLocalJurisdictionMember2022-12-310001593034us-gaap:StateAndLocalJurisdictionMemberus-gaap:GeneralBusinessMember2022-12-310001593034us-gaap:InternalRevenueServiceIRSMembercountry:US2022-12-310001593034endp:CARESActMember2022-01-012022-12-310001593034endp:CARESActMember2020-01-012020-12-310001593034srt:MaximumMember2022-01-012022-12-310001593034us-gaap:ScenarioPlanMembersrt:MinimumMember2021-04-012021-04-300001593034us-gaap:ScenarioPlanMembersrt:MaximumMember2021-04-012021-04-300001593034us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001593034us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001593034endp:StockAwardMember2022-01-012022-12-310001593034endp:StockAwardMember2021-01-012021-12-310001593034endp:StockAwardMember2020-01-012020-12-310001593034us-gaap:ReorganizationChapter11DebtorInPossessionMember2022-12-310001593034us-gaap:ReorganizationChapter11DebtorInPossessionMember2022-01-012022-12-310001593034us-gaap:ReorganizationChapter11DebtorInPossessionMember2021-12-310001593034endp:Endo401kPlanMatchingTierOneMember2022-01-012022-12-310001593034endp:Endo401kPlanMatchingTierTwoMember2022-01-012022-12-310001593034endp:Endo401kPlanMember2022-01-012022-12-31

For the fiscal year ended December 31, 2022

or

For the transition period from        to

Ireland						68-0683755
State or other jurisdiction of incorporation or organization						(I.R.S. Employer Identification No.)
First Floor, Minerva House, Simmonscourt Road
Ballsbridge, Dublin 4,			Ireland			Not Applicable
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code: 011-353-1-268-2000

Securities registered pursuant to Section 12(b) of the Act: None (1)

(1)			On August 26, 2022, Endo International plc’s ordinary shares, which previously traded on the Nasdaq Global Select Market under the symbol ENDP, began trading exclusively on the over-the-counter market under the symbol ENDPQ. On September 14, 2022, Nasdaq filed a Form 25-NSE with the United States Securities and Exchange Commission and Endo International plc’s ordinary shares were subsequently delisted from the Nasdaq Global Select Market. On December 13, 2022, Endo International plc’s ordinary shares were deregistered under Section 12(b) of the Securities Exchange Act of 1934, as amended.

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes

☐

No

☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes

☐

No

☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

☒

No

☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes

☒

No

☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☒

Non-accelerated filer

☐

Smaller reporting company

☒

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b).

☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes

☐

No

☒

The aggregate market value of the voting common equity (ordinary shares) held by non-affiliates as of June 30, 2022 (the last business day of the registrant’s most recently completed second fiscal quarter) was $109,653,452 based on a closing sale price of $0.47 per share as reported on The Nasdaq Global Select Market on that date. Ordinary shares held by each officer and director have been excluded since such persons and beneficial owners may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. The registrant has no non-voting ordinary shares authorized or outstanding.
The number of ordinary shares, nominal value $0.0001 per share outstanding as of February 27, 2023 was 235,219,612.

						Page
Forward-Looking Statements						i
PART I
Item 1.			Business			1
Item 1A.			Risk Factors			17
Item 1B.			Unresolved Staff Comments			52
Item 2.			Properties			52
Item 3.			Legal Proceedings			53
Item 4.			Mine Safety Disclosures			53
PART II
Item 5.			Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities			54
Item 6.			Reserved			54
Item 7.			Management’s Discussion and Analysis of Financial Condition and Results of Operations			54
Item 7A.			Quantitative and Qualitative Disclosures About Market Risk			75
Item 8.			Financial Statements and Supplementary Data			76
Item 9.			Changes in and Disagreements with Accountants on Accounting and Financial Disclosure			76
Item 9A.			Controls and Procedures			76
Item 9B.			Other Information			76
Item 9C.			Disclosure Regarding Foreign Jurisdictions that Prevent Inspections			76
PART III
Item 10.			Directors, Executive Officers and Corporate Governance			77
Item 11.			Executive Compensation			77
Item 12.			Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters			77
Item 13.			Certain Relationships and Related Transactions, and Director Independence			77
Item 14.			Principal Accountant Fees and Services			77
PART IV
Item 15.			Exhibit and Financial Statement Schedules			78
Item 16.			Form 10-K Summary			82
Signatures						83

Because these statements reflect our current views concerning future events, these forward-looking statements involve risks and uncertainties including, without limitation, the timing or results of any pending or future litigation, investigations, claims, actual or contingent liabilities, settlement discussions, negotiations or other adverse proceedings, including proceedings involving opioid-related matters, antitrust matters and tax matters with the U.S. Internal Revenue Service (IRS); unfavorable publicity regarding the misuse of opioids; the status, progress and/or outcome of our ongoing bankruptcy proceedings; changing competitive, market and regulatory conditions; changes in legislation; our ability to obtain and maintain adequate protection for our intellectual property rights; the impacts of competition such as those related to the loss of VASOSTRICT® exclusivity; the timing and uncertainty of the results of both the research and development and regulatory processes, including regulatory decisions, product recalls, withdrawals and other unusual items; domestic and foreign health care and cost containment reforms, including government pricing, tax and reimbursement policies; technological advances and patents obtained by competitors; the performance, including the approval, introduction and consumer and physician acceptance of new products and the continuing acceptance of currently marketed products; our ability to develop or expand our product pipeline and to continue to develop the market for XIAFLEX® and other branded or unbranded products; the impact that known and unknown side effects may have on market perception and consumer preference; the success of any acquisition, licensing or commercialization; the effectiveness of advertising and other promotional campaigns; the timely and successful implementation of any strategic and/or optimization initiatives; the uncertainty associated with the identification of and successful consummation and execution of external corporate development initiatives and strategic partnering transactions; our ability to obtain and successfully manufacture, maintain and distribute a sufficient supply of products to meet market demand in a timely manner; and the other risks and uncertainties more fully described under the caption “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K and in other reports that we file with the Securities and Exchange Commission (SEC).

Experienced and dedicated management team. We have a highly skilled and customer-focused management team in critical leadership positions across Endo. Our senior management team has extensive experience in the pharmaceutical industry, including improving business performance through organic revenue growth, operational and commercial excellence and through the identification, consummation and integration of licensing and acquisition opportunities. This experience is demonstrated through a proven track record of developing products and businesses.

Operational excellence. We have efficient, high-quality manufacturing capabilities across a diversified array of dosage forms in the U.S. and India. We believe our comprehensive suite of technology, manufacturing and development competencies increases the likelihood of success in commercializing high-barrier-to-entry products and obtaining first-to-file and first-to-market status on future products, yielding more sustainable market share and profitability. For example, our expanding capabilities in the rapidly growing U.S. market for sterile products afford us with a broader and more diversified product portfolio and a greater selection of targets for potential development.

Growth of our branded Specialty Products portfolio while leveraging the strength of our Established Products portfolio. We have assembled a portfolio of branded products offered by our Branded Pharmaceuticals segment in the areas of urology, orthopedics, endocrinology and bariatrics, among others. Additional information on these product portfolios is included below under the heading “Products Overview.”

Optimizing our portfolios to focus on differentiated products. By leveraging operational efficiency and taking actions to optimize our cost structure when appropriate, we aim to be low-cost producers of high-barrier-to-entry products, including products that meet the evolving needs of hospitals and health systems, including RTU sterile injectable products, and first-to-file and first-to-market generic opportunities that are difficult to formulate or manufacture or face complex legal and regulatory challenges. We believe that focusing on products with these characteristics will result in products with longer life cycles and higher profitability than products without these characteristics.

Continuing proactive diversification of our business. Our primary focus is on organic growth. However, we plan to continue to evaluate and, where appropriate, execute on opportunities to expand through the licensing or acquisition of products or companies in areas that will serve patients and customers and that we believe will offer attractive growth characteristics and margins. In particular, we intend to continue to enhance our product lines by acquiring or licensing rights to additional products and regularly evaluating selective acquisition opportunities.

R&D expertise. Our R&D efforts are focused on the development of a diversified portfolio of innovative and clinically differentiated product candidates. For example, in recent years, our Branded Pharmaceuticals research has focused on leveraging our expertise in collagenase clostridium histolyticum (CCH) and seeking additional novel indications for this class of biologics. Our Sterile Injectables and Generic Pharmaceuticals segments seek out and develop high-barrier-to-entry products, with an emphasis on complex sterile injectable products, such as RTU products, and first-to-file or first-to-market opportunities. We periodically review our R&D pipeline in order to better direct investment toward those opportunities that we expect will deliver the greatest returns. Our current R&D pipeline consists of products in various stages of development and reflects our expanded focus on Sterile Injectables products and solutions. For additional detail, see “Select Development Projects.” Our R&D and regulatory affairs staff is based primarily in India and the U.S.

Targeted sales and marketing capabilities. Our sales and marketing activities are based in the U.S. and Canada and primarily focus on the promotion of our Specialty Products portfolio and Sterile Injectables segment.

In addition to advertising in professional journals, participating in medical meetings and conventions and utilizing direct mail and internet programs to provide descriptive product literature and scientific information, we have also utilized both branded and unbranded marketing and public relations campaigns across digital, social and television platforms to reach our target consumers. For example, during the first quarter of 2022, we launched a new Dupuytren’s contracture (DC) condition awareness campaign featuring real patients and, during the fourth quarter of 2021, we launched a new multi-channel branded advertising campaign for XIAFLEX® for the treatment of Peyronie’s disease (PD), including our first-ever television commercial for XIAFLEX®.

			2022						2021						2020
Specialty Products:
XIAFLEX®			$	438,680					$	432,344					$	316,234
SUPPRELIN® LA			113,011						114,374						88,182
Other Specialty (1)			70,009						86,432						92,662
Total Specialty Products			$	621,700					$	633,150					$	497,078
Established Products:
PERCOCET®			$	103,943					$	103,788					$	110,112
TESTOPEL®			38,727						43,636						35,234
Other Established (2)			86,772						113,043						139,356
Total Established Products			$	229,442					$	260,467					$	284,702
Total Branded Pharmaceuticals (3)			$	851,142					$	893,617					$	781,780

(1)    Products included within Other Specialty include AVEED®, NASCOBAL® Nasal Spray and QWO®.

•SUPPRELIN® LA, which is a soft, flexible 12-month hydrogel implant based on our hydrogel polymer technology that delivers histrelin acetate, a gonadotropin-releasing hormone agonist, and is indicated for the treatment of CPP in children.

•NASCOBAL® Nasal Spray, which is a prescription nasal spray used as a supplement to treat vitamin B12 deficiency.

This portfolio has also included QWO® (collagenase clostridium histolyticum-aaes), an injectable treatment for moderate to severe cellulite in the buttocks of adult women launched in March 2021. However, in December 2022, the Company announced it would be ceasing the production and sale of QWO® in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.

			2022						2021						2020
VASOSTRICT®			$	253,696					$	901,735					$	785,646
ADRENALIN®			114,304						124,630						152,074
Other Sterile Injectables (1)			221,633						239,732						301,127
Total Sterile Injectables (2)			$	589,633					$	1,266,097					$	1,238,847

•VASOSTRICT®, which is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. We offer VASOSTRICT® in multiple formulations, including the RTU pre-mix bottle we launched in February 2022.

XIAFLEX® is currently approved by the FDA and marketed in the U.S. for the treatment of both DC and PD (two separate indications). In early 2020, we announced that we had initiated our XIAFLEX® development program for the treatment of plantar fibromatosis, for which we anticipate Phase 2 top-line data by the end of the first quarter of 2023. We also initiated a proof-of-concept study in plantar fasciitis during the fourth quarter of 2022. We may in the future develop our XIAFLEX® product for potential additional indications, advancing our strategy of developing non-surgical orthopedic care interventions.

			2022						2021						2020
AmerisourceBergen Corporation			35		%				36		%				33		%
McKesson Corporation			26		%				32		%				27		%
Cardinal Health, Inc.			20		%				22		%				24		%

Several of this segment’s products, such as PERCOCET®, TESTOPEL® and SUPPRELIN® LA, face generic and/or other forms of competition. The degree of generic and/or other competition facing this segment could increase in the future.

This segment’s products, including VASOSTRICT® and ADRENALIN®, face generic and/or other forms of competition. During the first quarter of 2022, multiple competitive generic alternatives to VASOSTRICT® were launched, beginning with a generic that was launched at risk and began shipping toward the end of January 2022. Since then, additional competitive alternatives entered the market, including authorized generics. The degree of generic and/or other competition facing this segment is expected to increase in the future.

Our products are subject to different patent expiration dates. For example, our patents related to NASCOBAL® Nasal Spray expire in 2024, our patents related to AVEED® expire in 2027 and our patents related to ADRENALIN® expire in 2035.

XIAFLEX® is a biological product. We own or have licensed rights to patents and patent applications related to XIAFLEX®, including drug product and methods of manufacture patents and patent applications that will expire into the late 2030s and methods of use patents and patent applications for uses such as plantar fibromatosis that will expire into the late 2030s/early 2040s.

The civil FCA and similar state laws impose liability on any person or entity who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The qui tam provisions of the FCA and similar state laws allow a private individual to bring civil actions on behalf of the federal or state government and to share in any monetary recovery. The U.S. Federal Physician Payments Sunshine Act and similar state laws impose reporting requirements for various types of payments to physicians and teaching hospitals. Failure to comply with reporting requirements under these laws could subject manufacturers and others to substantial civil money penalties. In addition, government entities and private litigants have asserted claims under state consumer protection statutes against pharmaceutical and medical device companies for alleged false or misleading statements in connection with the marketing, promotion and/or sale of pharmaceutical and medical device products, including state investigations of the Company regarding vaginal mesh devices previously sold by certain of our operating subsidiaries and investigations and litigation by certain government entities regarding the prior promotional practices of certain of our operating subsidiaries with respect to opioid products.

In Canada, the Regulations Amending the Patented Medicines Regulations (Additional Factors and Information Reporting Requirements) (the Amendments) came into force on July 1, 2022. The Amendments made a number of changes to the regulation of Canadian drug prices by the PMPRB. The PMPRB is an administrative board with a mandate to protect Canadians from excessive pricing of patented medicines. Pharmaceutical manufacturers that are patentees are required to report applicable patents and file sales information so the PMPRB can monitor for excessive pricing as long as the product is considered to be a patented medicine. If it is determined the average price for a patented medicine is too high based on pricing tests developed by the PMPRB, a payment must be made to the PMPRB to offset the excessive revenues that were generated and/or the price of the medicine must be reduced. The PMPRB’s authority to regulate the price of a drug product is linked to patent protection, specifically when there is a patent to an invention that is intended or capable of being used for medicine or for the preparation or production of medicine.

Name

Age

Position and Offices

Blaise Coleman

49

President and Chief Executive Officer

Patrick Barry

55

Executive Vice President and President, Global Commercial Operations

Mark T. Bradley

54

Executive Vice President and Chief Financial Officer

Matthew J. Maletta

51

Executive Vice President and Chief Legal Officer and Company Secretary

James P. Tursi, M.D.

58

Executive Vice President, Global Research & Development

You can access our filings through the SEC’s internet site: www.sec.gov (intended to be an inactive textual reference only).

You may also access copies of the Company’s filings with the Canadian Securities Administrators on SEDAR through their internet site: www.sedar.com (intended to be an inactive textual reference only).

•We operate in a highly competitive industry.

•We are subject to risks and uncertainties associated with the Chapter 11 Cases (as defined below).

•We are regularly the subject of material legal proceedings, including significant lawsuits, product liability claims, governmental investigations and product recalls.

•Our ability to fund our operations, maintain adequate liquidity and meet our financing obligations is reliant on our operations, which are subject to significant risks and uncertainties.

•Agreements between branded pharmaceutical companies and generic pharmaceutical companies are facing increased government scrutiny and we may be subject to additional investigations or litigation.

•Our ability to protect and maintain our proprietary and licensed third-party technology, which is vital to our business, is uncertain.

•Future changes to tax laws could materially adversely affect us.

•Irish law differs from the laws in effect in the U.S. and may afford less protection to our shareholders.

Certain of our branded products do not currently compete with on-market generic products but are likely to face generic competition in the future. The entrance of generic competitors can occur at any time and cannot be predicted with certainty. For additional information on our patent protection, refer to Part I, Item 1 of this report “Business” under the caption “Patents, Trademarks, Licenses and Proprietary Property.” Generic products we currently sell with generic exclusivity could in the future be subject to competition from other generic competitors. Some of our other branded and generic products, such as VASOSTRICT®, already face generic competition and are at risk of additional generic competitors entering the market. During the first quarter of 2022, multiple competitive generic alternatives to VASOSTRICT® were launched, beginning with a generic that was launched at risk and began shipping toward the end of January 2022. Since then, additional competitive alternatives entered the market, including authorized generics.

Various manufacturers have filed ANDAs seeking FDA approval for generic versions of certain of our key pharmaceutical products including, but not limited to, VASOSTRICT®, ADRENALIN® and AVEED®. In connection with such filings, these manufacturers have challenged the validity and/or enforceability of one or more of the underlying patents protecting our products.

For example, in the case of VASOSTRICT®, beginning in April 2018, Par Sterile Products, LLC (PSP LLC) and Par Pharmaceutical, Inc. (PPI) received notice letters from Eagle and other companies advising of the filing by such companies of ANDAs/NDAs for generic versions of VASOSTRICT® (vasopressin IV solution (infusion)) 20 units/ml and/or 200 units/10 ml. Beginning in May 2018, PSP LLC, PPI and Endo Par Innovation Company, LLC (EPIC) filed lawsuits against Eagle and other generic filers in the U.S. District Court for the District of Delaware or New Jersey. We reached settlements and voluntarily dismissed the suits against many of these filers. The remaining Delaware cases against Eagle and Amneal Pharmaceuticals LLC were consolidated and a trial was held in July 2021. In August 2021, the court issued an opinion holding that Eagle’s proposed generic product would not infringe PPI’s asserted patent claims. The court made no finding regarding the validity of the patents. We appealed the ruling. In August 2022, the Federal Circuit affirmed the District of Delaware’s decision: (i) that Eagle’s proposed generic product would not infringe PPI’s asserted patent claims and (ii) denying the issuance of a declaratory judgment that Eagle’s planned sale of generic product would infringe under 35 U.S.C. § 271(a) and (b). During the first quarter of 2022, multiple competitive generic alternatives to VASOSTRICT® 20 units/ml were launched, beginning with Eagle’s generic that was launched at risk and began shipping toward the end of January 2022. Since then, additional competitive alternatives entered the market, including authorized generics. These launches began to significantly impact both Endo’s market share and product price toward the middle of the first quarter of 2022, and the effects of competition have since increased. This competition could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Our products may cause known or unknown adverse or other side effects. If we or our partners, suppliers or brands are negatively impacted by publicity, media coverage, market perception or consumer preference, it could impact the commercial viability of our products, which could have a material adverse effect on our business, financial condition, results of operations and cash flows. For example, in December 2022, we announced we would be taking certain actions to cease the production and sale of QWO® in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.

			2022						2021						2020
AmerisourceBergen Corporation			35		%				36		%				33		%
McKesson Corporation			26		%				32		%				27		%
Cardinal Health, Inc.			20		%				22		%				24		%

The manufacture of biologic products requires significant expertise and capital investment. Although we manufacture CCH, which is included in XIAFLEX®, in our Horsham, Pennsylvania facility, we have limited experience in manufacturing biologic products. Biologics such as CCH require processing steps that are highly complex and generally more difficult than those required for most chemical pharmaceuticals. In addition, TESTOPEL® is manufactured using a unique, proprietary process. If the manufacturing processes are disrupted at the facilities where our biologic products are manufactured, it may be difficult to find alternate manufacturing sites. We may encounter difficulties with the manufacture of CCH and the active ingredient of TESTOPEL®, which could delay, disrupt or halt our manufacture of such products and/or product candidates, result in supply disruption or delay, product recalls or product liability claims, require write-offs or otherwise have a material adverse effect on our business, financial condition, results of operations and cash flows.

Due to these disruptions and other factors, including changes in our workforce availability and increased demand for some of our critical care products, our ability to meet our obligations to third-party distribution partners may be negatively impacted. We have delivered, and in the future we or our third-party providers may deliver, notices of the occurrence of force majeure or similar events under certain of our third-party contracts, which could result in prolonged commercial disputes and ultimately legal proceedings to enforce contractual performance and/or recover losses. Any such occurrences could result in significant management distraction and use of resources and, in the event of an adverse judgment, could result in significant cash payments. Further, the publicity of any such dispute could harm our reputation and make the negotiation of any replacement contracts more difficult and costly, thereby prolonging the effects of any resulting disruption in our operations. Such disruptions could be acute with respect to certain of our raw material suppliers where we may not have readily accessible alternatives or alternatives may take longer to source than usual. While we attempt, when possible, to mitigate our raw material supply risks through stock management and alternative sourcing strategies, some raw materials are only available from one source. Any of these disruptions could harm our ability to meet consumer demand, including any increase in demand for any of our products, including our critical care products used during a pandemic.

We have experienced, and expect to continue to experience, changes in customer demand as the COVID-19 pandemic continues to evolve, which are difficult to predict. For example, certain of our products that are physician administered, including XIAFLEX®, generally experienced decreased sales volumes during the COVID-19 pandemic due to reduced physician office activity and patient office visits because of the COVID-19 pandemic. While these products have generally been recovering since early 2020, they have at times continued to be impacted by COVID-19-related and, more recently, other market conditions for specialty product office-based procedures, including medical and administrative staff shortages in physicians’ offices, reduced physician office activity and lower numbers of in-person patient office visits. The pandemic and other market conditions also created a high backlog of demand for non-elective urology procedures, which has in certain cases reduced the utilization of XIAFLEX® by healthcare providers. Additionally, we believe that concerns by healthcare providers regarding economic uncertainty have impacted purchasing patterns of XIAFLEX®.

The U.S. Supreme Court, in FTC v. Actavis, determined that patent settlement agreements between generic and brand companies should be evaluated under the rule of reason, but provided limited guidance beyond the selection of this standard. Because the U.S. Supreme Court did not articulate the full range of criteria upon which a determination of the legality of such settlements would be based, or provide guidance on the precise circumstances under which such settlements would qualify as legal, there has been and may continue to be extensive litigation over what constitutes a reasonable and lawful patent settlement between a brand and generic company. The Company and/or its subsidiaries have been named in several such lawsuits. For example, beginning in May 2018, multiple complaints were filed in the U.S. District Court for the Southern District of New York against PPI, EPI and/or us, as well as other pharmaceutical companies, alleging violations of antitrust law arising out of the settlement of certain patent litigation concerning the generic version of Exforge® (amlodipine/valsartan). See Note 16. Commitments and Contingencies in the Consolidated Financial Statements included in Part IV, Item 15 of this report for more information.

There have been federal and state legislative efforts to overturn the FTC v. Actavis decision and make certain terms in patent settlement agreements per se unlawful. For example, some members of the U.S. Congress have proposed legislation that would limit the types of settlement agreements generic manufacturers and brand companies can enter into. The state of California enacted legislation, effective January 1, 2020, that deems a settlement of a patent infringement claim to be presumptively anticompetitive and allows the California Attorney General to seek monetary penalties if a generic company receives anything of value from the branded company and the generic company agrees to delay research and development, manufacturing, marketing or sales of the generic product for any period of time. The California law carves out from the definition of “anything of value” certain types of settlement terms and it allows the settling parties to rebut the presumption of anticompetitive harm.

In February 2014, EPI entered into a Deferred Prosecution Agreement and a Corporate Integrity Agreement (CIA) with HHS to resolve allegations regarding the promotion of LIDODERM®. In March 2013, our subsidiary Par Pharmaceutical Companies, Inc. (PPCI) entered into a CIA and plea agreement with the DOJ to resolve allegations regarding the promotion of MEGACE® ES, which was subsequently subsumed by EPI’s CIA. Those agreements placed certain obligations on us related to the marketing of our pharmaceutical products and our healthcare regulatory compliance program, including reporting requirements to the U.S. government, detailed requirements for our compliance program, code of conduct and policies and procedures and the requirement to engage an Independent Review Organization. We implemented procedures and practices to comply with the CIAs, including the engagement of an Independent Review Organization. In February 2020, Endo was notified that it had satisfied its CIA requirements and the 5-year term of Endo’s CIA has now concluded.

The FDA scheduled a Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee in March 2017 to discuss pre- and post-marketing data about the abuse of OPANA® ER and the overall risk-benefit of this product. The advisory committees were also scheduled to discuss abuse of generic oxymorphone ER and oxymorphone immediate-release products. In March 2017, the advisory committees voted 18 to eight, with one abstention, that the benefits of reformulated OPANA® ER no longer outweigh its risks. While several of the advisory committee members acknowledged the role of OPANA® ER in clinical practice, others believed its benefits were overshadowed by the continuing public health concerns around the product’s misuse, abuse and diversion. In June 2017, the FDA requested that we voluntarily withdraw OPANA® ER from the market and, in July 2017, after careful consideration and consultation with the FDA, we decided to voluntarily remove OPANA® ER from the market to the Company’s financial detriment. During the second quarter of 2017, we began to work with the FDA to coordinate an orderly withdrawal of the product from the market. By September 1, 2017, we ceased shipments of OPANA® ER to customers and the FDA withdrew the NDA in December 2020. These actions had an adverse effect on our revenues and, as a result of these actions, we incurred certain charges. Actions similar to these, such as recalls or withdrawals, could divert management time and attention, reduce market acceptance of all of our products, harm our reputation, reduce our revenues, lead to additional charges or expenses or result in product liability claims, any of which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

We are subject to federal and state laws prohibiting the presentation (or the causing to be presented) of claims for payment (by Medicare, Medicaid or other third-party payers) that are determined to be false or fraudulent, including presenting a claim for an item or service that was not provided. These false claims statutes include the federal civil FCA, which permits private persons to bring suit in the name of the government alleging false or fraudulent claims presented to or paid by the government (or other violations of the statutes) and to share in any amounts paid by the entity to the government in fines or settlement. Such suits, known as qui tam actions, have increased significantly in the healthcare industry in recent years. These actions against pharmaceutical companies, which do not require proof of a specific intent to defraud the government, may result in payment of fines to and/or administrative exclusion from the Medicare, Medicaid and/or other government healthcare programs.

• the judgment must be for a definite sum;

• the judgment must be final and conclusive; and

• the judgment must be provided by a court of competent jurisdiction.

Market Information. On August 17, 2022, we received a letter (the Notice) from The Nasdaq Stock Market LLC (Nasdaq) stating that, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that Endo’s ordinary shares would be delisted. In accordance with the Notice, trading of Endo’s ordinary shares was suspended at the opening of business on August 26, 2022. As a result, Endo’s ordinary shares began trading exclusively on the over-the-counter market on August 26, 2022. On the over-the-counter market, Endo’s ordinary shares, which previously traded on the Nasdaq Global Select Market under the symbol ENDP, began to trade under the symbol ENDPQ. On September 14, 2022, Nasdaq filed a Form 25-NSE with the SEC and Endo’s ordinary shares were subsequently delisted from the Nasdaq Global Select Market. On December 13, 2022, Endo’s ordinary shares were deregistered under Section 12(b) of the Exchange Act.

Dividends. We have never declared or paid any cash dividends on our ordinary shares and we currently have no plans to declare a dividend. We are permitted to pay dividends subject to limitations imposed by Irish law, the Bankruptcy Code and related rules during the pendency of the Chapter 11 Cases, the various agreements and indentures governing our indebtedness and the existence of sufficient distributable reserves. For example, the Companies Act requires Irish companies to have distributable reserves equal to or greater than the amount of any proposed dividend. Unless we are able to generate sufficient distributable reserves or create distributable reserves by reducing our share premium account, we will not be able to pay dividends.

Recent sales of unregistered securities; Use of proceeds from registered securities. There were no unregistered sales of equity securities by the Company during the three years ended December 31, 2022.

Purchase of Equity Securities by the issuer and affiliated purchasers. The following table reflects purchases of Endo International plc ordinary shares by the Company during the three months ended December 31, 2022:

Period						Total Number of Shares Purchased						Average Price Paid per Share						Total Number of Shares Purchased as Part of Publicly Announced Plan						Approximate Dollar Value of Shares that May Yet be Purchased Under the Plan (1)
October 1, 2022 to October 31, 2022						—						—						—						$	2,250,000,000
November 1, 2022 to November 30, 2022						—						—						—						$	2,250,000,000
December 1, 2022 to December 31, 2022						—						—						—						$	2,250,000,000
Three months ended December 31, 2022						—						—						—

•Total revenues in 2022 were $2,318.9 million compared to $2,993.2 million in 2021 as revenue decreases related to VASOSTRICT® and certain other products in our Sterile Injectables segment, as well as our Branded Pharmaceuticals and International Pharmaceuticals segments, were partially offset by increased revenues from our Generic Pharmaceuticals segment.

•Gross margin percentage in 2022 decreased to 52.9% from 59.2% in 2021, reflecting unfavorable changes in product mix resulting primarily from decreased VASOSTRICT® revenues.

•In November 2021, our PSP LLC subsidiary entered into the U.S. Government Agreement (as defined below), which is a cooperative agreement with the U.S. government to expand our Sterile Injectables segment’s fill-finish manufacturing production capacity and capabilities at our Rochester, Michigan plant to support the U.S. government’s national defense efforts regarding production of critical medicines advancing pandemic preparation. For further discussion, refer to Note 16. Commitments and Contingencies in the Consolidated Financial Statements included in Part IV, Item 15 of this report.

•During the first quarter of 2022, multiple competitive generic alternatives to VASOSTRICT® were launched, beginning with a generic that was launched at risk and began shipping toward the end of January 2022. Since then, additional competitive alternatives entered the market, including authorized generics. These launches began to significantly impact both Endo’s market share and product price toward the middle of the first quarter of 2022, and the effects of competition have since increased. Additionally, beginning late in the first quarter of 2022, COVID-19-related hospital utilization levels began to decline, resulting in significantly decreased market volumes for both branded and competing generic alternatives to VASOSTRICT®.

•In February 2022, we launched VASOSTRICT® in an RTU bottle, representing the first and only RTU formulation of the drug. The bottle formulation now represents a meaningful portion of the overall vasopressin market. Nevertheless, the factors described in the preceding bullet point could have a material adverse effect on our business, financial condition, results of operations and cash flows.

•In April 2022, we communicated the initiation of certain actions to streamline and simplify certain functions, including our commercial organization, to increase our overall organizational effectiveness and better align with current and future needs. In December 2022, we announced we would be taking certain additional actions to cease the production and sale of QWO® in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration. QWO® had been launched for the treatment of moderate to severe cellulite in the buttocks of adult women in March 2021. These actions are collectively referred to herein as the 2022 Restructuring Initiative. We have recorded and may continue to record certain charges to complete these actions in anticipation of realizing annualized cost savings. For further discussion of these actions, including a discussion of amounts recognized and information about any expected future charges, refer to Note 5. Restructuring in the Consolidated Financial Statements included in Part IV, Item 15 of this report.

			Returns and Allowances						Rebates						Chargebacks						Other Sales Deductions						Total
Balance, December 31, 2020			$	207,916					$	179,445					$	190,528					$	27,726					$	605,615
Current year provision			81,944						619,279						2,265,277						126,080						3,092,580
Prior year provision			(16,313)						(6,481)						(153)						(911)						(23,858)
Payments or credits			(90,431)						(595,775)						(2,270,469)						(128,939)						(3,085,614)
Balance, December 31, 2021			$	183,116					$	196,468					$	185,183					$	23,956					$	588,723
Current year provision			77,698						634,439						2,229,131						137,758						3,079,026
Prior year provision			(5,614)						(5,031)						(965)						(272)						(11,882)
Payments or credits			(88,034)						(612,600)						(2,238,647)						(116,429)						(3,055,710)
Balance, December 31, 2022			$	167,166					$	213,276					$	174,702					$	45,013					$	600,157

Developed Technology. Our developed technology assets subject to amortization have useful lives ranging from 6 years to 16 years, with a weighted average useful life of approximately 12 years. We determine amortization periods and methods of amortization for developed technology assets based on our assessment of various factors impacting estimated useful lives and the timing and extent of estimated cash flows of the acquired assets, including the strength of the intellectual property protection of the product (if applicable), contractual terms and various other competitive and regulatory issues.

License Rights. Our license rights subject to amortization have useful lives ranging from 7 years to 15 years, with a weighted average useful life of approximately 14 years. We determine amortization periods for licenses based on our assessment of various factors including the expected launch date of the product, the strength of the intellectual property protection of the product (if applicable), contractual terms and various other competitive, developmental and regulatory issues.

															% Change
			2022						2021						2022 vs. 2021
Total revenues, net			$	2,318,875					$	2,993,206					(23)		%
Cost of revenues			1,092,499						1,221,064						(11)		%
Gross margin			$	1,226,376					$	1,772,142					(31)		%
Gross margin percentage			52.9		%				59.2		%
Selling, general and administrative			777,169						861,760						(10)		%
Research and development			128,033						123,440						4		%
Acquired in-process research and development			68,700						25,120						NM
Litigation-related and other contingencies, net			478,722						345,495						39		%
Asset impairment charges			2,142,746						414,977						NM
Acquisition-related and integration items, net			408						(8,379)						NM
Interest expense, net			349,776						562,353						(38)		%
Loss on extinguishment of debt			—						13,753						(100)		%
Reorganization items, net			202,978						—						NM
Other income, net			(34,054)						(19,774)						72		%
Loss from continuing operations before income tax			$	(2,888,102)					$	(546,603)					NM

Total revenues, net. Total revenues in 2022 were $2,318.9 million compared to $2,993.2 million in 2021 as revenue decreases related to VASOSTRICT® and certain other products in our Sterile Injectables segment, as well as our Branded Pharmaceuticals and International Pharmaceuticals segments, were partially offset by increased revenues from our Generic Pharmaceuticals segment. Our revenues are further disaggregated and described below under the heading “Business Segment Results Review.”

Cost of revenues and gross margin percentage. During the years ended December 31, 2022 and 2021, Cost of revenues includes certain amounts that impact its comparability among periods, as well as the comparability of gross margin percentage, including amortization expense and amounts related to continuity and separation benefits, cost reductions and strategic review initiatives. The following table summarizes such amounts (in thousands):

			2022						2021
Amortization of intangible assets (1)			$	337,311					$	372,907
Amounts related to continuity and separation benefits, cost reductions and strategic review initiatives (2)			$	61,806					$	9,058

The decrease in Cost of revenues in 2022 was primarily due to decreased revenues and decreased amortization expense, partially offset by unfavorable changes in product mix resulting primarily from decreased VASOSTRICT® revenues, as well as increased costs for amounts related to continuity and separation benefits, cost reductions and strategic review initiatives.

The decrease in gross margin percentage in 2022 was primarily due to unfavorable changes in product mix resulting primarily from decreased VASOSTRICT® revenues.

Selling, general and administrative expenses. The decrease in 2022 was primarily due to decreased costs associated with our commercial investment in QWO® and certain legal matters. Additionally, in 2022, Selling, general and administrative expenses reflected the recovery of certain previously-incurred opioid-related legal expenses. These decreases were partially offset by increased Selling, general and administrative expenses associated with our investment in consumer marketing efforts supporting XIAFLEX® and certain strategic review initiatives, restructuring and/or other cost reduction initiatives, including costs incurred in connection with our bankruptcy proceedings, which are included in Selling, general and administrative expenses until the Petition Date and in Reorganization items, net thereafter. Refer to Note 5. Restructuring in the Consolidated Financial Statements included in Part IV, Item 15 of this report for further discussion of certain restructuring initiatives, including a discussion of amounts recognized and information about any expected future charges.

R&D expenses. Our R&D efforts are focused on the development of a diversified portfolio of innovative and clinically differentiated product candidates. The amount of R&D expense we record in any period varies depending on the nature and stage of development of our R&D programs, certain of which are further described below.

We continue to invest in our Branded Pharmaceuticals segment. In early 2020, we announced that we had initiated our XIAFLEX® development program for the treatment of plantar fibromatosis, for which we anticipate Phase 2 top-line data by the end of the first quarter of 2023. We also initiated a proof-of-concept study in plantar fasciitis during the fourth quarter of 2022. Additionally, until late 2022, we had been advancing our development programs for QWO®, which was launched in March 2021 for the treatment of moderate to severe cellulite in the buttocks of adult women. However, as further discussed in Note 5. Restructuring in the Consolidated Financial Statements included in Part IV, Item 15 of this report, in December 2022, we announced we would be ceasing the production and sale of QWO® in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.

The increase in R&D expense in 2022 was primarily driven by increased costs associated with our XIAFLEX® development programs, certain restructuring and other cost reduction initiatives and certain post-marketing commitments. These increases were partially offset by decreased costs associated with QWO®, including as a result of actions taken in connection with the discontinuation of QWO® discussed above. Refer to Note 5. Restructuring in the Consolidated Financial Statements included in Part IV, Item 15 of this report for further discussion of certain restructuring initiatives, including a discussion of amounts recognized and information about any expected future charges.

Acquired in-process research and development. Acquired in-process research and development charges are generally recognized in periods in which in-process research and development assets (with no alternative future use in other research and development projects) are acquired from third parties in connection with an asset acquisition, or when costs are incurred (up to the point of regulatory approval) for upfront or milestone payments to third parties associated with in-process research and development. The increase in Acquired in-process research and development charges in 2022 was primarily driven by the incurrence, during the second quarter of 2022, of expenses related to upfront payments associated with the 2022 Nevakar Agreement and the TLC Agreement of $35.0 million and $30.0 million, respectively, which are further described in Note 12. License, Collaboration and Asset Acquisition Agreements in the Consolidated Financial Statements included in Part IV, Item 15 of this report. This increase was partially offset by the incurrence, during 2021, of approximately $25.1 million of expenses, which primarily related to upfront payments associated with various license agreements. To the extent we enter into agreements to acquire in-process research and development in the future and/or incur expenses related to upfront or milestone payments to third parties associated with existing or potential future agreements, Acquired in-process research and development charges could increase in the future, and the amounts of any increases could be material.

Litigation-related and other contingencies, net. Included within Litigation-related and other contingencies, net are changes to our accruals for litigation-related charges. Our material legal proceedings and other contingent matters are described in more detail in Note 16. Commitments and Contingencies in the Consolidated Financial Statements included in Part IV, Item 15 of this report. Notwithstanding any relief that may be available as a result of our bankruptcy proceedings, it is possible that our legal proceedings, including those relating to opioid claims, could have a material adverse effect on our business, financial condition, results of operations and cash flows, including in the short term. For further discussion, refer to Note 1. Description of Business, Note 2. Bankruptcy Proceedings and Note 16. Commitments and Contingencies in the Consolidated Financial Statements included in Part IV, Item 15 of this report.

Asset impairment charges. The following table presents the components of our total Asset impairment charges for the years ended December 31, 2022 and 2021 (in thousands):

			2022						2021
Goodwill impairment charges			$	1,845,000					$	363,000
Other intangible asset impairment charges			288,701						7,811
Property, plant and equipment impairment charges			9,045						2,011
Disposal group impairment charges			—						42,155
Total asset impairment charges			$	2,142,746					$	414,977

Acquisition-related and integration items, net. Acquisition-related and integration items, net primarily consist of the net expense (benefit) from changes in the fair value of acquisition-related contingent consideration liabilities resulting from changes to our estimates regarding the timing and amount of the future revenues of the underlying products and changes in other assumptions impacting the probability of incurring, and extent to which we could incur, related contingent obligations. See Note 7. Fair Value Measurements in the Consolidated Financial Statements included in Part IV, Item 15 of this report for further discussion of our acquisition-related contingent consideration.

Interest expense, net. The components of Interest expense, net for the years ended December 31, 2022 and 2021 are as follows (in thousands):

			2022						2021
Interest expense			$	350,740					$	562,937
Interest income			(964)						(584)
Interest expense, net			$	349,776					$	562,353

Loss on extinguishment of debt. The amount in 2021 relates to the March 2021 Refinancing Transactions. Refer to Note 15. Debt in the Consolidated Financial Statements included in Part IV, Item 15 of this report for further discussion.

Reorganization items, net. Amounts relate to the net expense or income recognized during our bankruptcy proceedings required to be presented as Reorganization items, net under Accounting Standards Codification Topic 852, Reorganizations (ASC 852). Refer to Note 2. Bankruptcy Proceedings in the Consolidated Financial Statements included in Part IV, Item 15 of this report for further details. Costs related to our bankruptcy proceedings that were incurred prior to the Petition Date are generally reflected as Selling, general and administrative expenses in our Consolidated Statements of Operations. We expect to continue to incur significant expenses in connection with our ongoing bankruptcy proceedings and certain related transactions and it is possible that such costs will increase over time, particularly if we incur certain associated success-related and/or other contingent fees, which could be significant. In addition, the longer the Chapter 11 Cases continue, the higher our expenses for these matters could be.

Other income, net. The components of Other income, net for the years ended December 31, 2022 and 2021 are as follows (in thousands):

			2022						2021
Net gain on sale of business and other assets			$	(26,183)					$	(4,516)
Foreign currency (gain) loss, net			(2,087)						1,253
Net loss from our investments in the equity of other companies			378						453
Other miscellaneous, net			(6,162)						(16,964)
Other income, net			$	(34,054)					$	(19,774)

			2022						2021
Loss from continuing operations before income tax			$	(2,888,102)					$	(546,603)
Income tax expense			$	21,516					$	22,478
Effective tax rate			(0.7)		%				(4.1)		%

Discontinued operations, net of tax. The operating results of the Company’s Astora business, which the Board resolved to wind down in 2016, are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented. The following table provides the operating results of Astora Discontinued operations, net of tax, for the years ended December 31, 2022 and 2021 (in thousands):

			2022						2021
Litigation-related and other contingencies, net			$	—					$	25,000
Loss from discontinued operations before income taxes			$	(15,543)					$	(49,594)
Income tax benefit			$	(2,056)					$	(5,430)
Discontinued operations, net of tax			$	(13,487)					$	(44,164)

Revenues, net. The following table displays our revenue by reportable segment for the years ended December 31, 2022 and 2021 (dollars in thousands):

															% Change
			2022						2021						2022 vs. 2021
Branded Pharmaceuticals			$	851,142					$	893,617					(5)		%
Sterile Injectables			589,633						1,266,097						(53)		%
Generic Pharmaceuticals			795,457						740,586						7		%
International Pharmaceuticals (1)			82,643						92,906						(11)		%
Total net revenues from external customers			$	2,318,875					$	2,993,206					(23)		%

															% Change
			2022						2021						2022 vs. 2021
Specialty Products:
XIAFLEX®			$	438,680					$	432,344					1		%
SUPPRELIN® LA			113,011						114,374						(1)		%
Other Specialty (1)			70,009						86,432						(19)		%
Total Specialty Products			$	621,700					$	633,150					(2)		%
Established Products:
PERCOCET®			$	103,943					$	103,788					—		%
TESTOPEL®			38,727						43,636						(11)		%
Other Established (2)			86,772						113,043						(23)		%
Total Established Products			$	229,442					$	260,467					(12)		%
Total Branded Pharmaceuticals (3)			$	851,142					$	893,617					(5)		%

(1)Products included within Other Specialty include AVEED®, NASCOBAL® Nasal Spray and QWO®.

Certain of our products that are physician administered, including XIAFLEX®, generally experienced decreased sales volumes during the COVID-19 pandemic due to reduced physician office activity and patient office visits because of the COVID-19 pandemic. While these products have generally been recovering since early 2020, they have at times continued to be impacted by COVID-19-related and, more recently, other market conditions for specialty product office-based procedures, including medical and administrative staff shortages in physicians’ offices, reduced physician office activity and lower numbers of in-person patient office visits. The pandemic and other market conditions also created a high backlog of demand for non-elective urology procedures, which has in certain cases reduced the utilization of XIAFLEX® by healthcare providers. Additionally, we believe that concerns by healthcare providers regarding economic uncertainty have impacted purchasing patterns of XIAFLEX®. Changes in market conditions and certain other factors could result in revenue decreases or otherwise impact future periods, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

The increase in XIAFLEX® revenues in 2022 was primarily attributable to increased net price, partially offset by lower volumes. The decrease in volumes was primarily driven by continued challenging market conditions as further described above and the ongoing impact from a disruption experienced by our third-party specialty pharmacy provider during the third quarter of 2022. While we have since seen some recovery in volumes related to this disruption, volumes have not yet returned to pre-disruption levels.

The decrease in SUPPRELIN® LA revenues in 2022 was primarily attributable to decreased volumes, partially offset by increased net price.

The decrease in Other Specialty revenues in 2022 was primarily attributable to decreased NASCOBAL® Nasal Spray revenues, partially offset by increased AVEED® revenues.

The decrease in TESTOPEL® revenues in 2022 was primarily attributable to decreased volumes.

Sterile Injectables. The following table displays the significant components of our Sterile Injectables revenues from external customers for the years ended December 31, 2022 and 2021 (dollars in thousands):

															% Change
			2022						2021						2022 vs. 2021
VASOSTRICT®			$	253,696					$	901,735					(72)		%
ADRENALIN®			114,304						124,630						(8)		%
Other Sterile Injectables (1)			221,633						239,732						(8)		%
Total Sterile Injectables (2)			$	589,633					$	1,266,097					(53)		%

The decrease in VASOSTRICT® revenues in 2022 was primarily driven by decreases to both net price and volumes, which were primarily attributable to the impact of generic competition as well as lower overall market demand as COVID-19-related hospital utilization levels declined. During the first quarter of 2022, multiple competitive generic alternatives to VASOSTRICT® were launched, beginning with a generic that was launched at risk and began shipping toward the end of January 2022. Since then, additional competitive alternatives entered the market, including authorized generics. These launches began to significantly impact both Endo’s market share and product price toward the middle of the first quarter of 2022, and the effects of competition have since increased. Additionally, beginning late in the first quarter of 2022, COVID-19-related hospital utilization levels began to decline, resulting in significantly decreased market volumes for both branded and competing generic alternatives to VASOSTRICT®. In February 2022, we launched VASOSTRICT® in an RTU bottle, representing the first and only RTU formulation of the drug. The bottle formulation now represents a meaningful portion of the overall vasopressin market. Nevertheless, the factors described above could have a material adverse effect on our business, financial condition, results of operations and cash flows. For additional information, refer to Note 16. Commitments and Contingencies in the Consolidated Financial Statements included in Part IV, Item 15 of this report under the heading “Patent Matters.”

The decrease in ADRENALIN® revenues in 2022 was primarily attributable to decreased net price and volumes.

Generic Pharmaceuticals. The increase in Generic Pharmaceuticals revenues in 2022 was primarily attributable to revenues from varenicline tablets (our generic version of Pfizer Inc.’s Chantix®), which launched in September 2021, partially offset by competitive pressures on certain generic products.